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Abstract The treatment of acoustic neuromas (AN)
usually involves surgical excision or stereotactic radiosur-
gery. However, for large AN (mean diameter > 3 cm),
stereotactic radiosurgery is rarely used, leaving patients
with limited noninvasive treatment options. Recently, the
use of fractionated stereotactic radiotherapy (FSRT) has
been eVective in treating small to medium-sized AN. We
present a patient with a large AN treated with FSRT. The
patient was a 43-year-old man presenting with imbalance,
tinnitus, vertigo, and right-sided hearing decline associated
with vomiting and hydrocephalus. Magnetic resonance
(MR) imaging revealed a large, 3.8-cm, right cerebellopon-
tine-angle tumor compressing the fourth ventricle. Follow-
ing right frontal ventriculoperitoneal shunt placement, the
patient underwent FSRT for treatment of the tumor. Using
the Radionics X-Knife 4.0 3D treatment planning system, a
total of 54 Gy was delivered in 1.8-Gy daily fractions with
the prescription isodose line of 90%. Treatments were
delivered using a dedicated Varian 6/100 linear accelerator,
and head immobilization was achieved with the Gill-Tho-
mas-Cosman relocatable stereotactic frame. The patient
was subsequently evaluated with serial contrast-enhanced
MR imaging. Following FSRT, local control (deWned as the
absence of tumor progression) was achieved, and treatment
was well tolerated. There was no hearing-related, trigemi-
nal, or facial-nerve morbidity following FSRT at 63-month
follow-up. Treating a patient with a large AN with FSRT
resulted in local tumor control, with no trigeminal nerve,
facial nerve, or hearing-related morbidity. These results
support FSRT as a potential noninvasive treatment modal-
ity for AN some would consider too large for single-frac-
tion stereotactic radiosurgery (SRS).
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Introduction
The emergence of single-fraction stereotactic radiosurgery
(SRS) over the past two decades has greatly altered the
management of acoustic neuromas (AN)/vestibular sch-
wannomas by neurosurgeons, neuro-oncologists and radia-
tion oncologists. Multiple studies comparing SRS with
microsurgical excision have revealed that SRS has less
morbidity and is more cost eVective, with similar eYcacy to
surgical resection in controlling tumor progression for AN
with an average diameter of less than 3 cm [1–4]. However,
for large AN (mean diameter > 3 cm), decreased eYcacy
along with increasing facial and trigeminal nerve morbidity
and hearing loss following SRS make it a less attractive
treatment option in comparison with microsurgery [5, 6].
Fractionated stereotactic radiotherapy (FSRT) is a non-
invasive alternative treatment modality for tumors of the
skull base. Although FSRT requires multiple irradiation
sessions, recent reports have indicated that for AN with an
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eYcacy to SRS with signiWcantly reduced morbidity to
adjacent structures, particularly the trigeminal nerve
[7–10]. Because of this lower morbidity, FSRT has been
utilized for large (>3 cm) AN in a limited number of cases
[11]. To further enhance the existing knowledge regarding
the safety and eYcacy of FSRT for this patient population,
we detail our experience in treating a patient with a large
acoustic tumor.
Clinical materials and methods
Patient history
Our patient was a 43-year-old man with a past medical his-
tory of stroke who presented with a 1–2 year history of
worsening imbalance, along with new-onset bilateral tinni-
tus, vertigo, and right-sided hearing decline associated with
vomiting and hydrocephalus. Audiometric testing con-
Wrmed right sensorineural hearing loss, and magnetic reso-
nance (MR) imaging revealed a large tumor in the area of
the right cerebellopontine angle without deWnite invasion of
the internal auditory canal but with compression of the
fourth ventricle. The patient had no facial weakness or
changes in facial sensation. Due to his clinical and radio-
graphic Wndings, he underwent successful placement of a
right frontal ventriculoperitoneal shunt. Following shunt
placement, he was considered for microsurgery, SRS, or
FSRT for treatment of his cerebellopontine-angle lesion.
Although microsurgery was presented to the patient, he was
reluctant to undergo surgery, and due to the large size of the
tumor (mean diameter = 3.8 cm; maximum diameter =
4.1 cm), he chose FSRT over SRS.
Fractionated stereotactic radiotherapy treatment
All FSRT treatments were overseen by the neurosurgeon,
radiation oncologist and medical physicist. Following a
standardized testing simulation, the patient had FSRT
treatment planning for his right AN. After placement of a
Gill-Thomas-Cosman relocatable headframe for immobili-
zation (Integra Radionics, Burlington, MA, USA), a com-
puted tomography (CT) scan with contrast was obtained,
with the area of tumor scanned by 2-mm slices and the
remainder of the head by 4- and 8-mm slices. Treatment
planning (Fig. 1) was performed using the Radionics
X-Knife 4.0 three-dimensional (3D) planning system (Integra
Fig. 1 Anterior three-dimensional view on the X-Knife planning
software demonstrating the right cerebellopontine-angle acoustic
neuroma (blue), the Wve arcs used for treatment, and the 4.5-cm cone
(red) used to encompass the lesion during treatment planning for
fractionated stereotactic radiotherapy. The tumor is depicted in relation
to the brainstem (yellow), eyes (green), and optic chiasm (green). The
measured size of the tumor was 4.1 cm £ 3.5 cm £ 3.7 cm123
J Robotic Surg (2007) 1:227–230 229Radionics) as previously described [12]. The size of the
tumor was 4.1 cm £ 3.5 cm £ 3.7 cm (mean diameter =
3.8 cm), which was encompassed with two overlapping iso-
centers each measuring 4.5 cm in diameter. The patient
received daily fractions of 1.8 Gy until a total target dose of
54 Gy was administered. The radiation was prescribed to
the 90% isodose line using Wve rotational arcs and one
stationary beam. A mean dose of 0.082 Gy was delivered to
the brainstem per daily fraction. Thirty treatments were
stereotactically delivered over 6 weeks using a dedicated
Varian 6/100 linear accelerator (Varian Medical Systems,
Inc., Palo Alto, CA, USA). The patient tolerated the proce-
dure well, with no immediate or delayed posttreatment
complications.
Posttreatment course
Following FSRT, the patient was serially evaluated with
pre- and post-gadolinium-enhanced MR imaging and the
Gardner–Robertson hearing classiWcation system [13].
Local tumor control (deWned as the absence of tumor pro-
gression) was achieved and sustained. At his last follow-up
examination, 63 months after treatment, he continued to
demonstrate local tumor control, with no evidence of hear-
ing compromise in comparison with his hearing function
prior to FSRT. He experienced no signs or symptoms of tri-
geminal nerve morbidity, facial nerve morbidity, acute
complications, or other signs of radiation injury following
FSRT.
Discussion
Presenting typically with unilateral sensorineural hearing
loss, hydrocephalus, tinnitus, and/or imbalance, large AN
(mean diameter >3 cm) tend to enlarge within 1–2 years
from diagnosis, potentially resulting in signiWcant morbid-
ity due to brainstem compression and lower cranial nerve
damage by these lesions [14, 15].
The traditional standard of care for the treatment of large
AN has been microsurgical excision, which to date has
proven to be the treatment modality with the most long-
term eYcacy compared with SRS or observation alone [6,
14, 16]. However, with the recent advent of FSRT for small
and medium-sized AN demonstrating low morbidity and
excellent clinical eYcacy, it is possible that FSRT may rep-
resent an eVective noninvasive alternative to microsurgery
in patients with large AN [7, 10]. Previously, a small sub-
group (Wve patients with tumors >3 cm) of an extensive
acoustic neuroma FSRT series was reported to have experi-
enced adequate tumor control with minimal morbidity [11].
To contribute to the existing knowledge regarding FSRT
for large AN, we detailed our experience in a single patient.
Following operative ventriculoperitoneal shunt place-
ment for the treatment of our patient’s symptomatic hydro-
cephalus, subsequent FSRT resulted in complete local
tumor control. This long-term tumor control (>5 years)
came without subsequent return of hydrocephalus or
compromises in hearing, trigeminal nerve function, or
facial nerve function. These Wndings are comparable to
reported results for alternative treatment modalities for AN
of diameter >3 cm [6, 14, 17, 18]. This report indicates that
there may be a role for FSRT in the treatment of large AN
following appropriate management of more immediate
associated symptomatology.
Although the Wndings of this report are encouraging,
they must be tempered by the fact that this study involves a
single case, thereby limiting the ability to conclude deWni-
tively that FSRT is comparable/superior to microsurgery or
SRS for asymptomatic large AN. However, the fact that
this study supports the positive Wndings of a previous report
involving FSRT for Wve patients with large AN lends
strength to the hypothesis that FSRT may be a useful treat-
ment modality for AN >3 cm [11]. Future prospective ran-
domized controlled studies involving asymptomatic large
AN managed by observation, microsurgery, SRS, or FSRT
will be required to make a deWnitive determination of the
optimal treatment modality for this patient population.
Conclusion
In our experience of treating a patient with a large AN (max-
imum diameter = 4.1 cm; mean diameter = 3.8 cm), follow-
ing FSRT, the patient experienced long-term local tumor
control (>5 years) with no trigeminal nerve, facial nerve, or
hearing-related morbidity. These Wndings indicate that
FSRT may be a viable noninvasive treatment modality for
AN that may be too large to be successfully treated with
SRS. Subsequent prospective studies involving larger
patient sizes will be needed to adequately address this issue.
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